TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00089700

Recruitment Status : Unknown

Verified February 2005 by Tanox.
Recruitment status was: Active, not recruiting

First Posted : August 12, 2004

Last Update Posted : June 24, 2005

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by:

Tanox

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Primary Completion Date :	No date given
Study Completion Date :	No date given

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gathe JC, Hardwicke RL, Garcia F, Weinheimer S, Lewis ST, Cash RB. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study. J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):482-489. doi: 10.1097/QAI.0000000000002591.

To Top